Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $508.75 million. The enterprise value is $820.57 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
Earnings Date | May 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.16 million shares outstanding. The number of shares has increased by 3.03% in one year.
Current Share Class | 66.16M |
Shares Outstanding | 66.16M |
Shares Change (YoY) | +3.03% |
Shares Change (QoQ) | +0.30% |
Owned by Insiders (%) | 2.24% |
Owned by Institutions (%) | 33.10% |
Float | 34.45M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 11.74 |
PS Ratio | 0.86 |
Forward PS | 0.91 |
PB Ratio | 3.40 |
P/TBV Ratio | n/a |
P/FCF Ratio | 13.39 |
P/OCF Ratio | 13.05 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 13.91, with an EV/FCF ratio of 21.71.
EV / Earnings | n/a |
EV / Sales | 1.43 |
EV / EBITDA | 13.91 |
EV / EBIT | 20.60 |
EV / FCF | 21.71 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.92.
Current Ratio | 1.31 |
Quick Ratio | 0.80 |
Debt / Equity | 1.92 |
Debt / EBITDA | 5.50 |
Debt / FCF | 9.42 |
Interest Coverage | 1.03 |
Financial Efficiency
Return on equity (ROE) is -21.55% and return on invested capital (ROIC) is 4.21%.
Return on Equity (ROE) | -21.55% |
Return on Assets (ROA) | 3.24% |
Return on Invested Capital (ROIC) | 4.21% |
Return on Capital Employed (ROCE) | 7.70% |
Revenue Per Employee | $616,430 |
Profits Per Employee | -$36,067 |
Employee Count | 930 |
Asset Turnover | 0.75 |
Inventory Turnover | 2.01 |
Taxes
Income Tax | -5.29M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +85.30% in the last 52 weeks. The beta is 0.92, so Bioventus's price volatility has been similar to the market average.
Beta (5Y) | 0.92 |
52-Week Price Change | +85.30% |
50-Day Moving Average | 9.17 |
200-Day Moving Average | 10.09 |
Relative Strength Index (RSI) | 37.70 |
Average Volume (20 Days) | 352,598 |
Short Selling Information
The latest short interest is 742,601, so 1.12% of the outstanding shares have been sold short.
Short Interest | 742,601 |
Short Previous Month | 811,262 |
Short % of Shares Out | 1.12% |
Short % of Float | 2.16% |
Short Ratio (days to cover) | 1.83 |
Income Statement
In the last 12 months, Bioventus had revenue of $573.28 million and -$33.54 million in losses. Loss per share was -$0.52.
Revenue | 573.28M |
Gross Profit | 388.23M |
Operating Income | 39.84M |
Pretax Income | -48.54M |
Net Income | -33.54M |
EBITDA | 58.98M |
EBIT | 39.84M |
Loss Per Share | -$0.52 |
Full Income Statement Balance Sheet
The company has $41.58 million in cash and $356.06 million in debt, giving a net cash position of -$314.47 million or -$4.75 per share.
Cash & Cash Equivalents | 41.58M |
Total Debt | 356.06M |
Net Cash | -314.47M |
Net Cash Per Share | -$4.75 |
Equity (Book Value) | 185.60M |
Book Value Per Share | 2.25 |
Working Capital | 65.21M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $38.80 million and capital expenditures -$1.01 million, giving a free cash flow of $37.79 million.
Operating Cash Flow | 38.80M |
Capital Expenditures | -1.01M |
Free Cash Flow | 37.79M |
FCF Per Share | $0.57 |
Full Cash Flow Statement Margins
Gross margin is 67.72%, with operating and profit margins of 6.95% and -5.85%.
Gross Margin | 67.72% |
Operating Margin | 6.95% |
Pretax Margin | -8.57% |
Profit Margin | -5.85% |
EBITDA Margin | 10.29% |
EBIT Margin | 6.95% |
FCF Margin | 6.59% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.03% |
Shareholder Yield | -3.03% |
Earnings Yield | -6.63% |
FCF Yield | 7.47% |
Analyst Forecast
The average price target for Bioventus is $15.00, which is 95.06% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $15.00 |
Price Target Difference | 95.06% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 0.95 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.95 |
Piotroski F-Score | 6 |